Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Andrew Getahun to Antibodies, Monoclonal

This is a "connection" page, showing publications Andrew Getahun has written about Antibodies, Monoclonal.

 
Connection Strength
 
 
 
0.151
 
  1. Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016 12; 43:39-45.
    View in: PubMed
    Score: 0.086
  2. Wemlinger SM, Parker Harp CR, Yu B, Hardy IR, Seefeldt M, Matsuda J, Mingueneau M, Spilker KA, Cameron TO, Larrick JW, Getahun A, Cambier JC. Preclinical Analysis of Candidate Anti-Human CD79 Therapeutic Antibodies Using a Humanized CD79 Mouse Model. J Immunol. 2022 04 01; 208(7):1566-1584.
    View in: PubMed
    Score: 0.031
  3. Hardy IR, Anceriz N, Rousseau F, Seefeldt MB, Hatterer E, Irla M, Buatois V, Chatel LE, Getahun A, Fletcher A, Cons L, Pontini G, Hertzberg NA, Magistrelli G, Malinge P, Smith MJ, Reith W, Kosco-Vilbois MH, Ferlin WG, Cambier JC. Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol. 2014 Feb 15; 192(4):1641-50.
    View in: PubMed
    Score: 0.018
  4. Rutemark C, Alicot E, Bergman A, Ma M, Getahun A, Ellmerich S, Carroll MC, Heyman B. Requirement for complement in antibody responses is not explained by the classic pathway activator IgM. Proc Natl Acad Sci U S A. 2011 Oct 25; 108(43):E934-42.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)